Paper42686993
Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.
Nagler A and 22 others. Bone Marrow Transplant, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT. Papers, record 42686993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42686993
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35605254 | Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission. | Blood Adv | 2022 | https://conductscience.org/library/papers/35605254 | PubMed |
| 2 | 36949658 | Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission. | Br J Haematol | 2023 | https://conductscience.org/library/papers/36949658 | PubMed |
| 3 | 33030517 | Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/33030517 | PubMed |
| 4 | 30078459 | Acute myeloid leukaemia. | Lancet | 2018 | https://conductscience.org/library/papers/30078459 | PubMed |
| 5 | 38581695 | Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study. | Cancer | 2024 | https://conductscience.org/library/papers/38581695 | PubMed |
| 6 | 26010177 | Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy. | Am J Hematol | 2015 | https://conductscience.org/library/papers/26010177 | PubMed |
| 7 | 20629023 | Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. | Cancer | 2010 | https://conductscience.org/library/papers/20629023 | PubMed |
| 8 | 2143514 | Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. | J Immunol | 1990 | https://conductscience.org/library/papers/2143514 | PubMed |
| 9 | 33054609 | Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis. | Hematology | 2020 | https://conductscience.org/library/papers/33054609 | PubMed |
| 10 | 39439234 | Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia. | Br J Haematol | 2024 | https://conductscience.org/library/papers/39439234 | PubMed |
| 11 | 40927841 | Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. | Am J Hematol | 2025 | https://conductscience.org/library/papers/40927841 | PubMed |
| 12 | 33148668 | Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33148668 | PubMed |
| 13 | 40523209 | Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/40523209 | PubMed |
| 14 | 39018507 | Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/39018507 | PubMed |
| 15 | 38538862 | ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? | Leukemia | 2024 | https://conductscience.org/library/papers/38538862 | PubMed |
| 16 | 32375860 | Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. | J Hematol Oncol | 2020 | https://conductscience.org/library/papers/32375860 | PubMed |
| 17 | 38374026 | Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial. | Blood Cancer J | 2024 | https://conductscience.org/library/papers/38374026 | PubMed |
| 18 | 37342922 | Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37342922 | PubMed |
| 19 | 40305657 | Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703. | Blood Adv | 2025 | https://conductscience.org/library/papers/40305657 | PubMed |
| 20 | 6996481 | Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. | Am J Med | 1980 | https://conductscience.org/library/papers/6996481 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42686993
GET https://conductscience.org/api/papers/v1/42686993/authors?page=2